NCCN Guidelines (R) Insights Neuroendocrine and Adrenal Tumors, Version 2.2018 Featured Updates to the NCCN Guidelines JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK Shah, M. H., Goldner, W. S., Halfdanarson, T. R., Bergsland, E., Berlin, J. D., Halperin, D., Chan, J., Kulke, M. H., Benson, A. B., Blaszkowsky, L. S., Eads, J., Engstrom, P. F., Fanta, P., Giordano, T., He, J., Heslin, M. J., Kalemkerian, G. P., Kandeel, F., Khan, S. A., Kidwai, W., Kunz, P. L., Kuvshinoff, B. W., Lieu, C., Pillarisetty, V. G., Saltz, L., Sosa, J., Strosberg, J. R., Sussman, C. A., Trikalinos, N. A., Uboha, N. A., Whisenant, J., Wong, T., Yao, J. C., Burns, J. L., Ogba, N., Zuccarino-Catania, G. 2018; 16 (6): 693–702


The NCCN Guidelines for Neuroendocrine and Adrenal Tumors provide recommendations for the management of adult patients with neuroendocrine tumors (NETs), adrenal gland tumors, pheochromocytomas, and paragangliomas. Management of NETs relies heavily on the site of the primary NET. These NCCN Guidelines Insights summarize the management options and the 2018 updates to the guidelines for locoregional advanced disease, and/or distant metastasis originating from gastrointestinal tract, bronchopulmonary, and thymus primary NETs.

View details for DOI 10.6004/jnccn.2018.0056

View details for Web of Science ID 000435146500004

View details for PubMedID 29891520